NCT04527250View on ClinicalTrials.gov

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 18, 2020

Study Completion Date

December 30, 2020

Conditions
Healthy
Interventions
DRUG

ASC41

ASC41,1mg/table;5mg/table

DRUG

ASC41 placebo

ASC41 placebo,1mg/table;5mg/table

Trial Locations (1)

Unknown

Hunan provincial people's hospital, Changsha

Sponsors
All Listed Sponsors
collaborator

Hunan Provincial People's Hospital

OTHER

lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY